H. Lundbeck A/S: all 276 studies

Page 1 of 3. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• An Extension Trial of Asedebart in Participants With Congenital Adrenal HyperplasiaNot yet recruitingNCT07859293Phase 2
• A Trial of Lu AH69593 in Healthy ParticipantsRecruitingNCT07775261Phase 1
• A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have NarcolepsyRecruitingNCT07613710Phase 1
• A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsRecruitingNCT07514858Phase 2
• A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)RecruitingNCT07513441Phase 1
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationNCT06908226Phase 3
• Intermediate-Size Expanded Access Protocol (EAP) for LP352AvailableNCT06149663
• A Study of Eptinezumab in Pediatric Participants With Episodic MigraineRecruitingNCT05897320Phase 3
• A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaRecruitingNCT05669950Phase 1/2
• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineRecruitingNCT05164172Phase 3
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineRecruitingNCT04965675Phase 3
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheCompletedNCT05452239Phase 4Results posted
• Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedNCT05284019Phase 4Results posted
• A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsCompletedNCT05133323Phase 2Results posted
• A Study of Lu AF82422 in Participants With Multiple System AtrophyActive, not recruitingNCT05104476Phase 2Results posted
• A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)CompletedNCT05064397Phase 3Results posted
• Vortioxetine to Prevent Return of Symptoms in Children With DepressionTerminatedNCT05014919Phase 3Results posted
• Eptinezumab in Participants With Episodic Cluster HeadacheCompletedNCT04688775Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsCompletedNCT04418765Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of MigraineCompletedNCT04152083Phase 3Results posted
• Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaTerminatedNCT03230864Phase 3Results posted
• An Open Label Trial of ALD403 (Eptinezumab) in Chronic MigraineCompletedNCT02985398Phase 3Results posted
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic MigraineCompletedNCT02974153Phase 3Results posted
• Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With SchizophreniaCompletedNCT02892422Phase 3Results posted
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeTerminatedNCT02871297Phase 3Results posted
• Effect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaCompletedNCT02717195Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)CompletedNCT02709746Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)CompletedNCT02709655Phase 3Results posted
• An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease PatientsCompletedNCT02649608Phase 1Results posted
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic HypotensionCompletedNCT02586623Phase 4Results posted
• A Multicenter Assessment of ALD403 in Frequent Episodic MigraineCompletedNCT02559895Phase 3Results posted
• Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With AlzheimerCompletedNCT02553928Phase 4Results posted
• Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TreatmentCompletedNCT02400346Phase 3Results posted
• Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700CompletedNCT02333487Phase 1Results posted
• Investigating the Effect of Vortioxetine in Adult ADHD PatientsCompletedNCT02327013Phase 2Results posted
• A Multicenter Assessment of ALD403 in Chronic MigraineCompletedNCT02275117Phase 2Results posted
• Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet SyndromeTerminatedNCT02187809Phase 3Results posted
• Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's DiseaseCompletedNCT02079246Phase 3Results posted
• Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase InhibitorCompletedNCT02006654Phase 3Results posted
• Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With DonepezilCompletedNCT02006641Phase 3Results posted
• Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)TerminatedNCT01987960Phase 3Results posted
• Aripiprazole Once-monthly in Patients With SchizophreniaCompletedNCT01959035Phase 3Results posted
• Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With DonepezilCompletedNCT01955161Phase 3Results posted
• Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive DisorderTerminatedNCT01944969Phase 3Results posted
• Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TherapyCompletedNCT01942785Phase 3Results posted
• Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive DisorderCompletedNCT01942733Phase 3Results posted
• A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyTerminatedNCT01927055Phase 3Results posted
• Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentCompletedNCT01838681Phase 3Results posted
• Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentTerminatedNCT01837797Phase 3Results posted
• Brexpiprazole in Patients With SchizophreniaCompletedNCT01810783Phase 3Results posted
• Brexpiprazole in Patients With Acute SchizophreniaCompletedNCT01810380Phase 3Results posted
• Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With SchizophreniaCompletedNCT01795547Phase 3Results posted
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian CountriesCompletedNCT01571453Phase 3Results posted
• Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaCompletedNCT01556165Phase 3Results posted
• Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01500083Phase 3Results posted
• Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety DisorderCompletedNCT01491035Phase 2Results posted
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationCompletedNCT01488071Phase 3Results posted
• Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaCompletedNCT01479530Phase 3Results posted
• Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive DisorderCompletedNCT01422213Phase 3Results posted
• Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaCompletedNCT01377233Phase 2Results posted
• Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT01323478Phase 3Results posted
• A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)CompletedNCT01278173Phase 4Results posted
• Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in KoreaCompletedNCT01268891Phase 3Results posted
• A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseCompletedNCT01176240Phase 3Results posted
• Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut SyndromeCompletedNCT01160770Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT01140906Phase 3Results posted
• Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)CompletedNCT01132326Phase 3Results posted
• Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With EpilepsyCompletedNCT01128959Phase 3Results posted
• Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of CarbidopaCompletedNCT00983814Phase 2Results posted
• Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue SyndromeTerminatedNCT00977171Phase 2Results posted
• Escitalopram in Patients With Generalized Anxiety DisorderCompletedNCT00902564Phase 4Results posted
• Escitalopram in Patients With Social Anxiety DisorderCompletedNCT00902226Phase 4Results posted
• A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's DiseaseCompletedNCT00862940Phase 4Results posted
• Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's DiseaseTerminatedNCT00857649Phase 3Results posted
• Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's DiseaseTerminatedNCT00857233Phase 3Results posted
• Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)TerminatedNCT00856661Phase 3Results posted
• Safety Study of Sertindole Versus Risperidone Under Normal Conditions of UseCompletedNCT00856583Phase 3Results posted
• Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT00839423Phase 2Results posted
• Efficacy of Nalmefene in Patients With Alcohol DependenceCompletedNCT00812461Phase 3Results posted
• Safety and Efficacy of Nalmefene in Patients With Alcohol DependenceCompletedNCT00811941Phase 3Results posted
• Efficacy of Nalmefene in Patients With Alcohol DependenceCompletedNCT00811720Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly PatientsCompletedNCT00811252Phase 3Results posted
• Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderCompletedNCT00807248Phase 2Results posted
• A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using DroxidopaCompletedNCT00782340Phase 3Results posted
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00761306Phase 2Results posted
• Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)CompletedNCT00738062Phase 3Results posted
• Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00694304Phase 3Results posted
• Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic HypotensionCompletedNCT00657046Phase 2Results posted
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive DisorderCompletedNCT00635219Phase 3Results posted
• Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)CompletedNCT00633880Phase 3Results posted
• Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive EpisodesCompletedNCT00596817Phase 3Results posted
• Clobazam in Patients With Lennox-Gastaut SyndromeCompletedNCT00518713Phase 3Results posted
• Clobazam in Subjects With Lennox-Gastaut SyndromeCompletedNCT00162981Phase 2Results posted
• Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's DiseaseCompletedNCT00125138Phase 2Results posted
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Active, not recruitingNCT06719141Phase 3
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)Active, not recruitingNCT06706622Phase 3
• A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsCompletedNCT06701526Phase 4
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Active, not recruitingNCT06660394Phase 3
• A Trial Investigating Lu AG09222 With Ubrogepant in Participants With MigraineCompletedNCT06578585Phase 1
• A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye DiseaseActive, not recruitingNCT06557850Phase 1

← H. Lundbeck A/S overview and focus areas